Evogliptin

Evogliptin (INN; trade name Suganon) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea.[2]

Evogliptin
Clinical data
Trade namesSuganon
Other namesDA-1229
Routes of
administration
By mouth
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H26F3N3O3
Molar mass401.430 g·mol−1
3D model (JSmol)

References

  1. McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763.
  2. "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.